科创板IPO第五套标准重启后首家过会！

Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. successfully passed the IPO review by the Shanghai Stock Exchange on July 1, marking a significant case of implementing the China Securities Regulatory Commission's policy to enhance the inclusiveness of the Sci-Tech Innovation Board for unprofitable companies [1]. Group 1: Company Overview - Heyuan Biotechnology is an innovative biopharmaceutical company with a leading global plant bioreactor technology platform, focusing on the production of pharmaceuticals, pharmaceutical excipients, and research reagents [4]. - The company was established in November 2006 and transformed into a joint-stock company in December 2014, with a total share capital of 268.048646 million shares before the issuance [4]. Group 2: Financial Performance - The company's revenue for the reporting period was 13.3997 million yuan, 24.2641 million yuan, and 25.2161 million yuan, while the net profit attributable to the parent company was -148.6051 million yuan, -200.9395 million yuan, and -166.7474 million yuan [6]. Group 3: Major Shareholder Information - Yang Daichang is the largest shareholder, holding 15.03% of the shares directly and controlling a total of 29.25% of the voting rights through various agreements and entities [5]. Group 4: Key Questions from the Listing Committee - The listing committee inquired about the advanced nature of the core technologies related to the recombinant protein expression and purification platforms, as well as the reliability of specific performance indicators [7]. - Questions were raised regarding the market potential of the drug HY1001 compared to its competitors, including efficacy, indications, market acceptance, pricing, and cost [7]. - The committee also sought clarification on the operational standards for the production of medicinal rice, including breeding, planting, harvesting, storage, transportation, processing, and waste disposal, to ensure compliance and safety [8].